September 14, 2021
9 min watch
Save
VIDEO: Novel biologic agent for treatment of non-anterior uveitis under investigation
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video from the virtual Euretina congress, Quan Dong Nguyen, MD, MSc, speaks about ABY-035, a novel biologic compound that has been demonstrated to be a potent interleukin-17A inhibitor with unique pharmacological properties.
ABY-035 (Affibody) is currently under investigation in the LINNAEA international, multicenter, phase 2 study evaluating efficacy and safety in the treatment and prevention of relapse/recurrence of noninfectious intermediate, posterior or panuveitis.
Published by:
Sources/Disclosures
Collapse
Source:
Quan Dong Nguyen, MD, MSc
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.